Biopharma Execs Remain Optimistic Despite Political Headwinds

Drug pricing debates and uncertainty associated with Brexit are the issues most likely to keep biopharmaceutical executives awake at night. Nevertheless, senior figures remain optimistic about the industry’s prospects in 2020. These are among the major findings of a survey of 500 industry leaders and investors conducted by investment bank Jefferies.

“Nearly half of respondents believe that political and policy uncertainty present the greatest risks in 2020, with the latest Brexit developments and approaching UK and US elections seeing concerns around political volatility growing.